Ketamine is usually a Schedule III controlled substance. Currently, with certain exceptions, the use of ketamine for depression and similar behavioral health issues is “off label.” Which means While ketamine is authorised via the FDA for a few medical uses, it is not specifically accepted to treat depression.The efficacy of Spravato was evaluat